Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Results of using dara-CyBorD to treat patients with newly diagnosed or relapsed multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.12.18
Views: 792

Dr Habte Yimer - Texas Oncology, Tyler, USA

Dr Habte Yimer speaks to ecancer at ASH 2018 about the Lyra study, a phase II study that uses daratumumab (dara) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) to treat newly diagnosed and relapsed patients with multiple myeloma (MM).

He explains that PFS and OS results so far indicate that dara-CyBorD is comparable to dara-VMP.

Dr Yimer says this treatment might be particularly useful for patients with renal failure or if they are otherwise not a candidate for other treatment options. 

Related videos


no rating
Cancer care in Latin America

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation